What does Biomea Fusion, Inc. do?
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib…
What is Biomea Fusion, Inc.'s P/E and P/B ratio?
Biomea Fusion, Inc. has a P/E ratio of -2.0 and a P/B ratio of 3.48.
What is Biomea Fusion, Inc.'s debt-to-equity ratio?
Biomea Fusion, Inc. has a debt-to-equity ratio of 0.07.
How much does Biomea Fusion, Inc. owe compared with what it owns?
Biomea Fusion, Inc. owes $0.67 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Biomea Fusion, Inc.'s Positivity rank?
Biomea Fusion, Inc. is ranked #2,812 of 6,775 companies globally and #987 of 4,000 in United States on PositoAI, with a Positivity Score of 21,162.
Does Biomea Fusion, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Biomea Fusion, Inc..
Where can I read the latest news about Biomea Fusion, Inc.?
Recent headlines about Biomea Fusion, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Biomea Fusion, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Biomea Fusion, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.